These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30578945)
21. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression. Schmidt FM; Schröder T; Kirkby KC; Sander C; Suslow T; Holdt LM; Teupser D; Hegerl U; Himmerich H Psychiatry Res; 2016 May; 239():85-91. PubMed ID: 27137966 [TBL] [Abstract][Full Text] [Related]
22. Lipid Peroxidation and Immune Biomarkers Are Associated with Major Depression and Its Phenotypes, Including Treatment-Resistant Depression and Melancholia. Sowa-Kućma M; Styczeń K; Siwek M; Misztak P; Nowak RJ; Dudek D; Rybakowski JK; Nowak G; Maes M Neurotox Res; 2018 Feb; 33(2):448-460. PubMed ID: 29103192 [TBL] [Abstract][Full Text] [Related]
24. Psychopathological and sociodemographic features in treatment-resistant unipolar depression versus bipolar depression: a comparative study. Nuñez NA; Comai S; Dumitrescu E; Ghabrash MF; Tabaka J; Saint-Laurent M; Vida S; Kolivakis T; Fielding A; Low N; Cervantes P; Booij L; Gobbi G BMC Psychiatry; 2018 Mar; 18(1):68. PubMed ID: 29548306 [TBL] [Abstract][Full Text] [Related]
25. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. Feifel D; Malcolm B; Boggie D; Lee K J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206 [TBL] [Abstract][Full Text] [Related]
26. Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. Balestri M; Calati R; Souery D; Kautzky A; Kasper S; Montgomery S; Zohar J; Mendlewicz J; Serretti A J Affect Disord; 2016 Jan; 189():224-32. PubMed ID: 26451508 [TBL] [Abstract][Full Text] [Related]
27. Defining treatment-resistant depression: a comprehensive review of the literature. Trevino K; McClintock SM; McDonald Fischer N; Vora A; Husain MM Ann Clin Psychiatry; 2014 Aug; 26(3):222-32. PubMed ID: 25166485 [TBL] [Abstract][Full Text] [Related]
28. Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. Zaninotto L; Souery D; Calati R; Sentissi O; Kasper S; Akimova E; Zohar J; Montgomery S; Mendlewicz J; Serretti A Ann Clin Psychiatry; 2013 May; 25(2):97-106. PubMed ID: 23638440 [TBL] [Abstract][Full Text] [Related]
29. Interpersonal psychotherapy as add-on for treatment-resistant depression: A pragmatic randomized controlled trial. Souza LH; Salum GA; Mosqueiro BP; Caldieraro MA; Guerra TA; Fleck MP J Affect Disord; 2016 Mar; 193():373-80. PubMed ID: 26799332 [TBL] [Abstract][Full Text] [Related]
30. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. Fornaro M; Rocchi G; Escelsior A; Contini P; Martino M J Affect Disord; 2013 Mar; 145(3):300-7. PubMed ID: 22981313 [TBL] [Abstract][Full Text] [Related]
31. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression. Medeiros da Frota Ribeiro C; Riva-Posse P Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992 [TBL] [Abstract][Full Text] [Related]
32. A follow-up study on features of sensory gating P50 in treatment-resistant depression patients. Wang Y; Fang YR; Chen XS; Chen J; Wu ZG; Yuan CM; Yi ZH; Hong W; Zhang C; Cao L Chin Med J (Engl); 2009 Dec; 122(24):2956-60. PubMed ID: 20137481 [TBL] [Abstract][Full Text] [Related]
33. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095 [TBL] [Abstract][Full Text] [Related]
34. The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature. Johnston KM; Powell LC; Anderson IM; Szabo S; Cline S J Affect Disord; 2019 Jan; 242():195-210. PubMed ID: 30195173 [TBL] [Abstract][Full Text] [Related]
35. Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. De Carlo V; Calati R; Serretti A Psychiatry Res; 2016 Jun; 240():421-430. PubMed ID: 27155594 [TBL] [Abstract][Full Text] [Related]
36. The inflammatory marker GDF-15 is not independently associated with late-life depression. Teunissen CE; Durieux-Lu S; Blankenstein MA; Oude Voshaar RC; Comijs HC J Psychosom Res; 2016 Apr; 83():46-9. PubMed ID: 27020076 [TBL] [Abstract][Full Text] [Related]
37. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987 [TBL] [Abstract][Full Text] [Related]
38. Mood disorders and circulating levels of inflammatory markers in a longitudinal population-based study. Glaus J; von Känel R; Lasserre AM; Strippoli MF; Vandeleur CL; Castelao E; Gholam-Rezaee M; Marangoni C; Wagner EN; Marques-Vidal P; Waeber G; Vollenweider P; Preisig M; Merikangas KR Psychol Med; 2018 Apr; 48(6):961-973. PubMed ID: 28929992 [TBL] [Abstract][Full Text] [Related]